Biomarck Pharmaceuticals, Ltd today announced that it is delighted to have been invited to present Phase 2 clinical data from its study in NSCLC and an update on the Phase 2 study in ARDS at the JPM conference.
These two controlled clinical studies add to the breadth of clinical data observed in over 300 patients dosed with BIO-11006 which has already shown significant effect (p=0.029) in FEV1 in patients with COPD.
The NSCLC study was controlled with carboplatin/pemetrexed (SOC) and at 3 months showed an improvement in PR, less DP and a significant (p=0.02) improvement in ORR compared to SOC.
The ARDS clinical study compares BIO-11006 to placebo in established ARDS patients who are on a ventilator. This study has almost completed enrollment and clinical data is expected Q1, 2020
The safety profile of BIO-11006 is very encouraging with only cough and headache occurring in <5% of patients.
BIO-11006 is a novel patented peptide that inhibits the MARCKS protein. Phosphorylation of the MARCKS protein has been shown to stimulate cell division and movement. BIO-11006 is part of a portfolio of over 100 patented compounds owned by Biomarck.
Biomarck Pharmaceuticals, Ltd., is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, COPD and NSCLC, confirming safety and efficacy in these three potential indications. In vivo data demonstrate that BIO-11006 and other peptides in the Biomarck pipeline inhibit inflammation in dermatology and ophthalmology models. Potential indications include uveitis, dry eye, atopic dermatitis and psoriasis.
This press release may contain forward-looking statements. Forward-looking statements are not guarantees, and they involve risks, uncertainties, and assumptions. The information in the press release should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.